According to GuruFocus Insider Data, these are the largest CEO buys during the past week.
AXA Equitable Holdings CEO bought 49,000 shares
AXA Equitable Holdings Inc. (EQH, Financial) President and CEO Mark Pearson bought 49,000 shares on June 27 at a price of $20.34. The price of the stock has increased by 7.33% since.
AXA Equitable Holdings is a financial services company. It comprises two principal franchises, AXA Equitable Life Insurance Company and AllianceBernstein. The company has a market cap of $10.72 billion. Its shares traded at $21.83 with a price-earnings ratio of 14.36 as of July 5.
Net loss for the first quarter of 2019 was $775 million compared to net income of $214 million for the first quarter of 2018.
10% Owner AXA sold 40 million shares on June 7 at a price of $20.85. The price of the stock has increased by 4.7% since.
Liberty Latin America CEO bought 14,500 shares
Liberty Latin America Ltd. (LILA, Financial) President and CEO Balan Nair bought 14,500 shares on June 27 at a price of $17.22. The price of the stock has increased by 1.34% since.
Liberty Latin America is a telecommunications company. It offers communications and entertainment services including video, broadband internet, telephony and mobile services to its residential and business customers. The company has four reportable segments namely Cable and Wireless Communication, VTR and Liberty Puerto Rico. It generates a majority of its revenue from Cable and Wireless Communication. Geographically, the company gets a major share of its revenue from the United Kingdom. The company has a market cap of $3.16 billion. Its shares traded at $17.45 as of July 5.
Net loss for the three months ended March 31, 2019 was $42 million compared to $45 million for the three months ended March 31, 2018.
Senior Vice President and Chief Financial Officer Christopher J. Noyes bought 15,000 shares on June 27 at a price of $17.24. The price of the stock has increased by 1.22% since.
Karuna Therapeutics CEO bought 10,000 shares
Karuna Therapeutics Inc. (KRTX, Financial) President and CEO Steven M. Paul bought 10,000 shares on June 28 at a price of $23.04. The price of the stock has increased by 18.71% since.
Karuna Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. Their pipeline is built on the therapeutic potential of their lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. The company has a market cap of $617.45 million. Its shares traded at $27.35 as of July 5.
On July 2, 2019, Karuna Therapeutics announced the closing of its initial public offering of 6,414,842 shares of common stock at a public offering price of $16.00 per share. The shares commenced trading on the Nasdaq Global Market on June 28, 2019.
Director Bharat M. Chowrira bought 10,000 shares on July 2 at a price of $21.21. The price of the stock has increased by 28.95% since.
Director and 10% Owner Robert Nelsen bought 200,000 shares on July 2 at a price of $16. The price of the stock has increased by 70.94% since.
Director James Healy bought 700,000 shares on July 2 at a price of $16. The price of the stock has increased by 70.94% since.
10% Owner Arch Venture Partners IX, LLC bought 200,000 shares on July 2 at a price of $16. The price of the stock has increased by 70.94% since.
10% Owner Alexandria Venture Investments bought 30,000 shares on July 2 at a price of $16. The price of the stock has increased by 70.94% since.
Esperion Therapeutics CEO bought 5,000 shares
Esperion Therapeutics Inc. (ESPR, Financial) President and CEO Timothy M. Mayleben bought 5,000 shares on June 28 at a price of $46.00. The price of the stock has increased by 2.67% since.
Esperion Therapeutics is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment. The company has a market cap of $1.27 billion. Its shares traded at $47.23 as of July 5.
Esperion had a net income of $87.4 million for the first quarter of 2019 compared to a net loss of $46.1 million for the prior-year period in 2018.
Altus Midstream CEO bought 35,000 shares
Altus Midstream Co. (ALTM, Financial) CEO D. Clay Bretches bought 35,000 shares during the past week at the average price of $3.65.
Altus Midstream was formed through the business combination of Kayne Anderson Acquisition Corp. (KAAC), a special purpose acquisition company and Apache Corporation (APA) and operates as a subsidiary of Apache Corporation. Altus Midstream owns gas gathering, processing, and transmission assets in the Permian Basin of West Texas. The company has a market cap of $1.19 billion. Its shares traded at $3.66 with a price-earnings ratio of 66.55 as of July 5.
Net income for the first quarter of 2019 was $1.1 million.
Bretches bought 20,000 shares on June 14 at a price of $4.22; 20,000 shares on June 27 at a price of $3.65; and 15,000 shares on June 27 at a price of $3.64. The price of the stock has increased by 0.55% since.
For the complete list of stocks that bought by their company CEOs, go to: CEO Buys.
Disclosure: I do not own stock in any of the companies mentioned.
